Healthcare costs doubled when children had urinary tract infections caused by extended‐spectrum β‐lactamase‐producing bacteria. (27th November 2016)

• Record Type: Journal Article
• Authors: Nieminen, Oona; Korppi, Matti; Helminen, Merja
• Is Part Of: Acta pædiatrica. Volume 106:Number 2(2017)
• Page Start: 327
• Page End: 333
• Publication Date: 2016-11-27
• Subjects: Antimicrobial resistant organisms -- Extended‐spectrum beta‐lactamase -- Healthcare costs -- Length of stay -- Urinary tract infection; Pediatrics -- Periodicals; Pediatrics; 618.92
• DOI: 10.1111/apa.13656
• Languages: English
• ISSNs: 0803-5253

Abstract

Abstract: Aim: The impact of the emergence of antimicrobial resistant organisms has rarely been studied in children, including the healthcare costs of urinary tract infections (UTIs) caused by extended‐spectrum beta‐lactamase (ESBL)‐producing bacteria. We evaluated the effect of ESBL on UTI healthcare costs and risk factors for paediatric UTIs. Methods: This retrospective case–control study covered 2005–2014 and focused on children below 16 years of age treated in a University hospital: 22 children with UTIs caused by ESBL‐producing bacteria and 56 ESBL‐negative UTI controls. Results: The median healthcare costs were 3929 Euros for the 22 ESBL patients and 1705 Euros for the 56 controls (p = 0.015). The mean and standard deviation length of hospital stay was 7.4 (5.9) days for the ESBL group and 3.6 (2.3) days for the controls (p = 0.007), and the figures for antibiotic treatment were 12.3 (5.5) days versus 5.8 (3.0) days (p < 0.001), respectively. The odd ratios for ESBL were underlying disease (6.63, p = 0.013), previous hospitalisation (6.07, p = 0.009) and antibiotic prophylaxis (5.20, p = 0.035). Conclusion: Healthcare costs more than doubled when children had ESBL‐related UTIs, mainly due to their increased length of stay. Effective oral antibiotics are urgently needed to treat paediatric infections caused by ESBL‐producing bacteria.